Zuranolone: clinical trials recruiting now
3
Recruiting trials
4
Conditions studied
3
US states with sites
1
Countries
FDA drug label
- FDA-approved
- Yes. Zuranolone appears in the FDA drug-label database. Marketed as ZURZUVAE.
- Drug class
- Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator (FDA established pharmacologic class)
- Mechanism of action
- GABA A Receptor Positive Modulators (as stated on the FDA label)
- Boxed warning
- The FDA label for Zuranolone carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adults. ( 1 )
Phase breakdown
Phase 2 1
Not applicable 2
Conditions being studied
| Condition | Trials |
|---|---|
| Depression · Zuranolone for Depression | 3 |
| Depression, Postpartum | 1 |
| Post Stroke Depression | 1 |
| Postpartum Depression | 1 |
Recruiting trials involving Zuranolone
- A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone
- A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
- Allopregnanolone (Zuranolone) in Post-stroke Depression
Common questions
Is Zuranolone FDA-approved?
Yes, marketed as ZURZUVAE. Its FDA label carries a boxed warning.
How many recruiting trials involve Zuranolone?
3 recruiting trials across 4 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.